

DRUGS AFFECTING

ERECTILE DYSFUNCTION



Free Stock
Free Photo
Free Vector


DRUGS AFFECTING ERECTILE DYSFUNCTION

ILOs


By the end of this lecture you will be able to:

- ✚ Revise the haemodynamic changes inducing normal erection
- ✚ Interpret its different molecular control mechanisms
- ✚ Define erectile dysfunction [ED] and enumerate its varied risks
- ✚ List drugs inducing ED and reflect on some underlying mechanisms
- ✚ Correlate drugs used in treatment of ED to the etiopathogenesis
- ✚ Classify oral 1st line therapy relevant to; Mechanism / Utility / ADRs
- ✚ Compare the pharmacological difference of PDE₅ inhibitors
- ✚ Study the transurethral, intracavernous or topical 2nd line therapies;
Mechanism / Utility / ADRs
- ✚ Enumerate lines of treatment of priapism



Peripheral HAEMODYNAMIC CHANGES inducing ERECTION



FLACCID State



ERECT State



Pathophysiology

Mechanism of an erection

- * An erection occurs when the **amount of blood rushing to the penis is greater than the amount of blood flowing from it**
- * **A massive influx of blood accumulates** in the sinusoidal spaces due to **relaxation of smooth muscle & dilatation of arteries** → corpora cavernosa to swell (**tumescence**)
- * Tumescence compresses the veins that normally drain the penis → reduces **venous outflow** & maintains penile rigidity

Pathophysiology

Mechanism of an erection


- * A normal erection relies on the coordination:
 - Vascular
 - Neurological
 - Hormonal
 - Psychological
- * An erection can occur following direct genital stimulation or auditory or visual stimulation, aspects that contribute to the influx of blood to the penis

ERECTILE DYSFUNCTION


Persistent or recurrent inability to attain (acquire) & maintain (sustain) an erection (rigidity) sufficient for satisfactory sexual performance

“**Impotent**” is reserved for those men who experience erectile failure during attempted intercourse more than 75 % of the time.

Prevalence



Endothelial Dysfunction → Commonest Cause



I.M.P.O.T.E.N.C.E

Inflammatory	Prostatitis, urethritis
Mechanical	Peyronie's Disease, chordee
Psychological	Depression, performance anxiety, stress, relationship difficulties
Occlusive vascular	Art: Hypertension, smoking, hyperlipidemia, DM., peripheral vascular disease Ven: venous occlusion due to anatomical or degenerative changes
Trauma	Pelvic fracture, SC inj, penile trauma
Endocrine	Hypogonadism, hyperprolactinemia, hypo + hyperthyroidism
Neurologic	Parkinsons, multiple sclerosis, spina bifida, pelvic surgery, peripheral neuropathy
Chemical	Anti-HTN, anti-arrhythmics, antidepressants, anxiolytics, anti-androgens, anticonvulsants, alcohol, marijuana, anti-parkinson drugs, LHRH analogues
Extra factors	Prostatectomy, old age, CRF, cirrhosis

DRUGS ADVERSLY CAUSING ED

Drug Class	Specific drug examples
Beta-blockers Calcium-channel blockers Alpha-adrenergic agonists Cardiac glycosides	propranolol, metoprolol, atenolol verapamil, nifedipine clonidine digoxin
Thiazide diuretics Aldosterone antagonists	hydrochlorothiazide spironolactone
Fibric acid derivatives	gemfibrozil, clofibrate
Selective serotonin reuptake inhibitors Tricyclic antidepressants Other antidepressants	fluoxetine, sertraline, paroxetine, citalopram amitriptyline, desipramine, nortriptyline lithium
Benzodiazepines	lorazepam, alprazolam, diazepam
Histamine (H ₂) receptor antagonists	ranitidine, cimetidine
Butyrophenones and phenothiazines	haloperidol, prochlorperazine, chlorpromazine
Hydantoin anticonvulsants	phenytoin
Cytotoxic agents	cyclophosphamide, methotrexate
Recreational drugs	alcohol, cocaine, marijuana

DRUGS ADVERSLY CAUSING ED

Centrally Acting Drugs

DA>**NE** promote arousal / **5HT** action on $5HT_2 \rightarrow \downarrow$ DA release $\rightarrow \downarrow$ arousal

Most **ADDs** $\rightarrow \downarrow$ 5HT uptake;

non-selectively as TCAs
selectively as **SSRIs**

\uparrow 5HT in synapse
act on $5HT_2$

Peripherally; antagonize NO actions / \downarrow genital sensation \rightarrow **Delay ejaculation**

Treat Premature Ejaculation

- ✦ **Anti-psychotic drugs** \rightarrow DA antagonist + hyperprolactenemia
- ✦ **Anti-epileptic drugs** (phenytoin) \rightarrow have GABA effect
 \rightarrow antagonize Exc. Amino acid. $\rightarrow \uparrow$ sedation $\rightarrow \downarrow$ arousal.

Centrally acting anti-hypertensives

- ✦ **Methyl dopa, Reserpine** !!! $\rightarrow \downarrow$ arousal
- ✦ **Clonidine** $\rightarrow \downarrow$ arousal centrally / Vasoconstriction peripherally !!!

Other anti-hypertensives

- ✦ β_2 blockers \rightarrow -ve vasodilating β_2 + potentiate α_1 effect
- ✦ **Thiazide diuretics** \rightarrow \downarrow spinal reflex controlling erection + \downarrow arousal


\downarrow Desire

Anti-androgens

- ✦ **Finasteride** \rightarrow α reductase inhibitor (prevent production of active testosterone \rightarrow irreversible erectile dysfunction)
- ✦ **Cyproterone acetate** \rightarrow synthetic steroidal antiandrogen
- ✦ **Cimetidine** (high doses) / **Ketoconazole** / **Spirolactone** \rightarrow hyperprolactinemia + gynecomastia
- ✦ **Estrogen-containing medications**

Habituating Agents

- ✦ **Cigarette smoking** \rightarrow vasoconstriction + penile venous leakage
- ✦ **Alcohol** [small amounts] \rightarrow \uparrow desire + \downarrow anxiety + vasodilatation
- ✦ **Alcohol** [big amounts] \rightarrow \uparrow sedation + \downarrow desire
- ✦ **Chronic alcoholism** \rightarrow hypogonadism + polyneuropathy



Desire

Androgens

DRUGS TREATING ED

CENTRALLY

PERIPHERALLY

ORAL

Transurethral

Intracavernosal Inj.

L-arginine

eNOS

NO

Citrulline

Arachidonic Acid

Prostacyclin Synthase

Prostacyclin

~~Nitrates !!!~~

Guanylate Cyclase

cGMP

PDE₅

GMP

Protein Kinases
Protein Kinases

Adenylate Cyclase

cAMP

PDE_{2,3,4}

AMP

Prostaglandin Analogues

~~Salbutamol !!!~~

PDE₅ Inhibitors

- Sildenafil
- Vardenafil
- Tadalafil
- Avanafil

Papaverine

α₁

Phentolamine

SELECTIVE PDE₅ Inhibitors

Mechanism

- Sildenafil
- Vardenafil
- Tadalafil
- Avanafil

Inhibit PDE₅ → prevent breakdown of cGMP → **pertain vasodilatation → erection.**

They do not affect the libido, **so sexual stimulation is essential to a successful**



Pharmacodynamic action relevant to PDE₅ inhibition ►

- ✚ VSMCs of **Erectile Tissue of Penis** (vascular smooth muscle cells (VSMCs))
- ✚ Other VSMCs (**lung**, brain....) / **heart**
- ✚ Other non-VSMCs (**prostate**, **bladder**, **seminal vesicle**, **GIT**....)
- ✚ Platelets
- ✚ Other tissues; testis, sk. muscles, liver, kidney, pancreas,

Indications

✚ **Erectile dysfunction**; 1st line therapy. All types have similar efficacy

	Sildenafil	Vardenafil	Tadalafil
% Efficacy	74-84	73-83	72-81

- ✚ **Pulmonary hypertension**
- ✚ **BPH & premature ejaculation**

Selectivity on PDE₅ is not absolute and vary with each drug

- ✚ Can partially act on PDE targeting cGMP (6, 11, 9, 1) ★
- ✚ In higher doses it can act on PDE targeting cAMP (2,3,4, 10,...) ★

PDE 1 ★	Heart, brain, lung, smooth muscle
PDE 2 ★	Adrenal gland, heart, lung, liver, platelets
PDE 3 ★	Heart, lung, liver, platelets, adipose tissue, inflammatory cells
PDE 4 ★	Sertoli cells, kidney, brain, liver, lung, inflammatory cells
PDE 5 ★	Lung, platelets, vascular smooth muscle, heart
PDE 6 ★	Photoreceptor
PDE 7 ★	Skeletal muscle, heart, kidney, brain, pancreas, T lymphocytes
PDE 8 ★	Testes, eye, liver, skeletal muscle, heart, kidney, ovarv, brain, T lymphocyte
PDE 9 ★	Kidney, liver, lung, brain, possibly heart
PDE 10 ★	Testes, brain
PDE 11 ★	Skeletal muscle, prostate, kidney, liver, pituitary and salivary glands, testes

IHD / AMI

Headache/Flush
nasal congestion
Altered VISION

Back Pain

Sildenafil 10-fold selective
Vardenafil 16-fold selective
Tadalafil >200-fold selective

Give variability in ADRs



Common ADRs	Sildenafil	Vardenafil	Tadalafil
Headache %	14	10	15
Flushing %	12	11	3
Nasal	Congestion	Rhinitis	Congestion
Dyspepsia %	7	3	15
Abnormal vision %	> 4	< 2	
Myalgia & Back pain %	-	-	5
Sperm functions	-	-	↓?
Q-T prolongation	-	↑	-

Major less common ADRs

1. IHD & AMI > patients on big dose or on nirates
2. Hypotension > patients on α-blockers than other antihypertensives
3. Bleeding; epistaxis.....etc.
4. Priapism; if erection lasts longer than 4 hours → emergency situation

Major rare ADRs

1. Ischemic Optic Neuropathy; can cause sudden loss of vision
2. Hearing loss

Pharmacokinetic profile difference of PDE5 inhibitors

Absorption; Fatty food interferes with **Sildenafil & Vardenafil** absorption
→ so taken on empty stomach / at least 2 hrs after food
Tadalafil & Avanafil are not affected by food

Metabolism; All by hepatic CYT3A4; Tadalafil > the rest thus;
↑ADRs with enzyme inhibitors; erythro & clarithromycin, ketoconazole, cimetidine, tacrolimus, fluvoxamine, amiodarone...etc.
↓ efficacy with enzyme inducers; rifampicin, carbamazepine, phenytoin

Administration

All drugs are given only once a day	Sildenafil	Vardenafil	Tadalafil
Dosage (mg)	50-100	10-20	10-20
Time of administration before intercourse (hrs.)	1	1	1-12
Onset of action (min)	30-60	30-60	<30-45
Duration of action (hrs.)	4	4-5	36

NB. **Avanafil** has the advantage of been given 30 min before intercourse
Tadalafil must be given every 72 hrs if used with enzyme inhibitors

Contraindications

- ✚ Hypersensitivity to drug
- ✚ Patients with history of AMI / stroke / fatal arrhythmias <6 month
- ✚ Nitrates → total contraindication / ? PDEIs in small dose + spacing at least 24hrs (48 hrs with *Tadalafil*) for fear of developing IHD/AMI due to severe hypotension (*see detailed mechanism in antianginal drugs*)

Precautions

- ✚ With α blockers [except tamsulosin] → orthostatic hypotension
- ✚ With hepato/renal insufficiency
- ✚ With bleeding tendencies [leukemia's, hemophilia, Vit K deficiency, antiphospholipid syndrome,...etc]
- ✚ With *quinidine, procainamide, amiodarone* (class I & III antiarrhythmics) (*Vardenafil*)
- ✚ Dose adjustment; *when using drugs that have interaction on hepatic liver microsomal enzymes i.e inhibitors or inducers.*
- ✚ Retinitis pigmentosa

Testosterone

- ✚ Given to those with hypogonadism or hyperprolactenemia
 - ✚ Given for promotion of desire.
-

Apomorphine

- ✚ A dopamine agonist on D₂ receptors.
 - ✚ Activates arousal centrally; Erectogenic + Little promotion of desire
 - ✚ Given sublingual / Acts quickly.
 - ✚ Not FDA approved / Weaker than PDE₅ Is
 - ✚ Given in mild-moderate cases / psychogenic / PDE₅ Is contraindication
 - ✚ ADRs: nausea, headache, and dizziness but safe with nitrate
-

Oral phentolamine → α_1 blocker / debatable efficacy

Yohimbine → Central and peripheral α_2 agonist → Aphrodetic + Erectogenic
but low efficacy and many CV side effects

Trazodone → Antidepressant, a 5HT reuptake inhibitor → priapism

Korean Ginseng → Questionable / may be a NO donor.

TRANSURETHRAL

Alprostadil; PG E1 → ↑cAMP

Synthetic + more stable

Applied by a special applicator into penile urethra
& acts on corpora cavernosa → Erection

✚ Low - Intermediate Efficacy

✚ Minimal systemic effects / Rarity of drug interactions.

ADRs

✚ Variable penile pain

✚ Urethral bleeding / Urethral tract infection

✚ Vasovagal reflex / Hypotension

✚ Priapism or Fibrosis → rare

Topical

20% Papaverine; ↑cAMP + cGMP



2% Minoxidil; NO donor + K channel opener

2% Nitroglycerine

+ a drug absorption enhancers

Low efficacy / No FDA approval

Female Partner can develop → hypotension, headache → vaginal absorption.



1. Alprostadil; PG E1 → ↑cAMP

Needs training → Erection → after 5-15 min

lasts according to dose injected →

May develop fear of self injury / Discontinuation

ADRs

- ✚ Pain or bleeding at injection site
- ✚ Cavernosal fibrosis
- ✚ Priapism

2. Papaverine; PG E1 → ↑cAMP

3. Phentolamine; α_1 blocker



Intracavernosal Inj.


3 combined in severe cases

Treatment of Priapism

- ✚ A medical emergency
- ✚ Aspirate blood to decrease intracavernous pressure.
- ✚ Intracavernous injection of **Phenylephrine** → α_1 agonist
→ detumescence

DRUGS AFFECTING

ERECTILE DYSFUNCTION



Free Download
Free Download
Free Download

9000 2400K